Eden vs NovoCare Pharmacy (Wegovy) (2026): prices, structure, verdict

On tirzepatide, only Eden has a rankable figure: $408 a month all-in; NovoCare Pharmacy (Wegovy)↗ does not offer tirzepatide.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Eden is cheaper: $198 versus $349 a month all-in — a $151 monthly gap, $1,812 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Eden: the record, condensed

Start with the load-bearing figure: $408 a month, all-in, is what Eden charges for tirzepatide at the 10 mg basis. Pricing steps with the dose here: from $348 at entry to $408 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $720 a year, which is why every ranking on this site uses the larger number.

Inside that $408 sits a mandatory $99-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $309, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #16 of 17 in the verified tirzepatide index — $193/month above the floor (NexLife↗, $215) — and sits $41 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,896.

On semaglutide, the number that matters at Eden is $198 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Inside that $198 sits a mandatory $99-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $99, and it is not a price anyone can actually pay, because the membership cannot be declined.

To place the number: #10 of 20 verified programs, with the floor $65/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $151 a month. A year at this figure: $2,376 monthly-billed.

Operationally at Eden: shipping included; commitment membership auto-renews; cancellation membership auto-renews until cancelled; pharmacy not publicly named — ask in writing before paying; states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Eden page · visit Eden ↗

NovoCare Pharmacy (Wegovy): the record, condensed

Start with the load-bearing figure: $349 a month, all-in, is what NovoCare Pharmacy (Wegovy) charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes NovoCare Pharmacy (Wegovy) unusually easy to compare and unusually easy to leave.

To place the number: #0 of 20 verified programs, with the floor $216/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth nothing a month — at which point brand deserves the first look. A year at this figure: $4,188 monthly-billed.

Operationally at NovoCare Pharmacy (Wegovy): shipping included (or retail via savings card); commitment none; cancellation no subscription; pharmacy named (Novo Nordisk direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NovoCare Pharmacy (Wegovy) page · visit NovoCare Pharmacy (Wegovy) ↗

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: Eden at $198, NovoCare Pharmacy (Wegovy) at $349 — a $151 monthly spread that compounds to $1,812 over a maintenance year and $3,624 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $151 gap is exactly what it appears to be.

Eden’s total includes a mandatory $99/month membership; NovoCare Pharmacy (Wegovy) has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $151/month spread into medication: $1,812 a year equals roughly 9.2 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Eden $198/mo month-to-month versus NovoCare Pharmacy (Wegovy) $349/mo month-to-month. Same winner on both bases — Eden leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Eden $594 monthly; NovoCare Pharmacy (Wegovy) $1,047 monthly — best path favors Eden by $453. 6 months: Eden $1,188 monthly; NovoCare Pharmacy (Wegovy) $2,094 monthly — best path favors Eden by $906. 12 months: Eden $2,376 monthly; NovoCare Pharmacy (Wegovy) $4,188 monthly — best path favors Eden by $1,812. 24 months: Eden $4,752 monthly; NovoCare Pharmacy (Wegovy) $8,376 monthly — best path favors Eden by $3,624.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: Eden publishes “most states”; NovoCare Pharmacy (Wegovy) publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: NovoCare Pharmacy (Wegovy) names its network (Novo Nordisk direct / retail partners); Eden does not, which shifts the burden of verification onto your intake questions.

Exit terms: Eden — membership auto-renews; membership auto-renews until cancelled. NovoCare Pharmacy (Wegovy) — none; no subscription.

Evidence: Eden source-verified (captured 2026-08-05); NovoCare Pharmacy (Wegovy) source-verified (2026-08-10).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between Eden and NovoCare Pharmacy (Wegovy)

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Eden: membership auto-renews until cancelled; NovoCare Pharmacy (Wegovy): no subscription) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings